Targets › TNKS
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Oncology; next expected readout Mar 2027.
Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, necroptosis, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination…. (UniProt, O95271)
Open in Phaseline: the race on TNKS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Allarity Therapeutics | 2X-121 Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Tankyrase 1/2 inhibitor | PARP1, PARP2, TNKS2, TNKS | Phase 2 | Advanced Ovarian Cancer | Mar 2027 |
| Eluciderm | ELU42 Tankyrase inhibitor combined with derivatized hyaluronic acid (DHA77) excipient for topica | TNKS | Phase 1 | Diabetic Foot Ulcer | – |
Diabetic Foot Ulcer (1) Advanced Ovarian Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.